- Home
- VATE vs BCAB Comparison
VATE vs BCAB Comparison
Compare VATE & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VATE
- BCAB
- Stock Information
- Founded
- VATE 1994
- BCAB 2007
- Country
- VATE United States
- BCAB United States
- Employees
- VATE N/A
- BCAB N/A
- Industry
- VATE Metal Fabrications
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- VATE Industrials
- BCAB Health Care
- Exchange
- VATE Nasdaq
- BCAB Nasdaq
- Market Cap
- VATE 98.2M
- BCAB 22.3M
- IPO Year
- VATE 1996
- BCAB 2020
- Fundamental
- Price
- VATE $5.50
- BCAB $0.40
- Analyst Decision
- VATE
- BCAB Buy
- Analyst Count
- VATE 0
- BCAB 2
- Target Price
- VATE N/A
- BCAB $1.00
- AVG Volume (30 Days)
- VATE 18.2K
- BCAB 519.0K
- Earning Date
- VATE 08-06-2025
- BCAB 08-07-2025
- Dividend Yield
- VATE N/A
- BCAB N/A
- EPS Growth
- VATE N/A
- BCAB N/A
- EPS
- VATE N/A
- BCAB N/A
- Revenue
- VATE $1,066,100,000.00
- BCAB $11,000,000.00
- Revenue This Year
- VATE N/A
- BCAB N/A
- Revenue Next Year
- VATE N/A
- BCAB N/A
- P/E Ratio
- VATE N/A
- BCAB N/A
- Revenue Growth
- VATE N/A
- BCAB N/A
- 52 Week Low
- VATE $3.25
- BCAB $0.24
- 52 Week High
- VATE $13.79
- BCAB $2.53
- Technical
- Relative Strength Index (RSI)
- VATE 49.15
- BCAB 48.83
- Support Level
- VATE $5.20
- BCAB $0.36
- Resistance Level
- VATE $5.62
- BCAB $0.43
- Average True Range (ATR)
- VATE 0.25
- BCAB 0.03
- MACD
- VATE 0.06
- BCAB -0.00
- Stochastic Oscillator
- VATE 75.41
- BCAB 43.40
About VATE INNOVATE Corp.
Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments which are; The infrastructure segment is comprised of DBM Global Inc, a fully integrated industrial construction, structural steel, and facility maintenance provider that provides fabrication and erection of structural steel and heavy steel plate services, The Life Sciences segment is comprised of Pansend Life Sciences which seeks to develop products to treat early osteoarthritis of the knee and aesthetic and medical technologies for the skin, and Spectrum segment is comprised of HC2 Broadcasting Holdings Inc which operates over-the-air broadcasting station across the United States.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.